Skip to content

A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing

A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00855933
Enrollment
60
Registered
2009-03-05
Start date
2009-01-31
Completion date
2009-02-28
Last updated
2013-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Brief summary

This is a randomized, controlled, examiner-blind, parallel group, four week clinical study comparing brushing plus flossing to brushing alone in healthy adults with mild-to-moderate gingivitis.

Interventions

DEVICEExperimental Floss

Experimental Glide® floss with cetylpyridinium chloride (\ 13% dry weight CPC)

Sponsors

Procter and Gamble
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* at least 18 years of age; * physically able to floss his/her teeth; * refrained from performing oral hygiene the morning of the Baseline visit; * have measurable gingivitis on at least 5 test sites; * in good general health.

Exclusion criteria

* severe periodontal disease * atypical discoloration or pigmentation in the gingival tissue; * meaningful malocclusion of the anterior teeth; * fixed facial orthodontic appliances; * use of antibiotics within two weeks of the baseline visit and at any time during the study; * any diseases or conditions that could be expected to interfere with the subject safely completing the study.

Design outcomes

Primary

MeasureTime frameDescription
Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale4 weeksA whole-mouth average Lobene Modified Gingival Index was calculated by summing the scores and dividing by the number of sites graded (excludes missing teeth & sites not graded). Whole mouth average can range from 0 (normal) to 4 (severe inflammation). For each tooth, six gingival areas (distobuccal, buccal, mesiobuccal, mesiolingual, lingual, and distolingual) were scored using the following scale: 0=Normal (Absence of inflammation, 1=Mild inflammation (slight change in color, little change in texture) of any portion of but not the entire marginal or papillary gingival unit, 2=Mild inflammation criteria as above but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the marginal or papillary gingival unit, 4=Severe inflammation (marked redness, edema and/or hypertrophy, spontaneous bleeding or ulceration) of the marginal or papillary gingival unit.

Countries

Guatemala, United States

Participant flow

Participants by arm

ArmCount
Brushing Only
Control - Subjects will refrain from flossing. Subjects will brush teeth Crest® Cavity Protection toothpaste and Oral-B® Indicator soft, manual toothbrush once daily.
30
Brushing + Flossing
Experimental - Subjects will floss once daily with the experimental floss. Subjects will brush teeth Crest® Cavity Protection toothpaste and Oral-B® Indicator soft, manual toothbrush once daily.
30
Total60

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicBrushing OnlyTotalBrushing + Flossing
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
30 Participants60 Participants30 Participants
Age Continuous29.5 years
STANDARD_DEVIATION 10.08
28.7 years
STANDARD_DEVIATION 9.71
27.8 years
STANDARD_DEVIATION 9.41
Region of Enrollment
Guatemala
30 participants60 participants30 participants
Sex: Female, Male
Female
26 Participants53 Participants27 Participants
Sex: Female, Male
Male
4 Participants7 Participants3 Participants
Whole Mouth Average Lobene Modified Gingival Index2.41 Units on a scale
STANDARD_DEVIATION 0.28
2.40 Units on a scale
STANDARD_DEVIATION 0.27
2.38 Units on a scale
STANDARD_DEVIATION 0.27

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 300 / 30
serious
Total, serious adverse events
0 / 300 / 30

Outcome results

Primary

Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale

A whole-mouth average Lobene Modified Gingival Index was calculated by summing the scores and dividing by the number of sites graded (excludes missing teeth & sites not graded). Whole mouth average can range from 0 (normal) to 4 (severe inflammation). For each tooth, six gingival areas (distobuccal, buccal, mesiobuccal, mesiolingual, lingual, and distolingual) were scored using the following scale: 0=Normal (Absence of inflammation, 1=Mild inflammation (slight change in color, little change in texture) of any portion of but not the entire marginal or papillary gingival unit, 2=Mild inflammation criteria as above but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the marginal or papillary gingival unit, 4=Severe inflammation (marked redness, edema and/or hypertrophy, spontaneous bleeding or ulceration) of the marginal or papillary gingival unit.

Time frame: 4 weeks

ArmMeasureValue (MEAN)Dispersion
Brushing OnlyWhole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale1.84 units on a scaleStandard Error 0.047
Brushing + FlossingWhole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale1.73 units on a scaleStandard Error 0.047
p-value: 0.12695% CI: [-0.03, 0.24]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026